A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1

Exclusion Criteria

• •1\. History of conditions affecting bone or mineral metabolism
• •1. Previous treatment with an enzyme replacement therapy (ERT) or any advanced therapeutic agent (e.g., gene therapy) for the treatment of hypophosphatasia (HPP) or any treatment for osteoporotic diseases
• •2. Previous exposure to any medication or investigational agent potentially affecting bone structure, muscle volume, muscle strength, or muscle or nerve function
• •3. Diagnosis of hyperparathyroidism
• •4. Diagnosis of hypoparathyroidism, unless secondary to HPP
• •5. New fracture within 12 weeks before first dosing